Business health coalitions expect health plans to continue delivering what employers want for their employees and dependents in 2007. And while it's difficult to predict the future, there are four reasons for this bullishness, according to the National Business Coalition on Health (NBCH).

  1. The drive for quality improvement. NBCH collected data from 250 health plans and ranked them according to how closely they met its criteria in each of 10 categories. Since health plans want to earn the highest possible ranking, one way to do so is to collaborate with employers and coalitions to improve the delivery of care.
  2. Closer cooperation between health plans and employers. For this reason alone, employers are likely to get what they want from health plans, and health plans are likely to become more adept at delivering what employers want.
  3. Use of a standard tool. More employers and health coalitions are using NBCH's survey tool. Health plans do not need to respond to a wide variety of requests for information from many different employers. By using a standard request form, employers and health plans streamline the process.
  4. Ongoing tool refinement. NBCH has been using and improving its proprietary tool since 1996 to collect data on the care that plans deliver to employees and dependents.

Greater collaboration sought for 2007

  • 36% of health plans are pooling data with at least one other health plan to measure and report practitioner or provider feedback
  • 20% of health plans are pooling data with another health plan to facilitate feedback from practitioners to consumers
  • 47% of HMOs and 57% of PPOs collaborate with employers to improve how plans deliver care to patients with asthma.
  • 28% of health plans are giving periodic financial rewards to providers

Move toward tiered networks

  • 21 percent of health plans offer tiered networks of primary care physicians
  • 21 percent of plans use tiered networks of specialists
  • 23 percent of plans include medical groups or IPAs in tiered networks

Source: Information on the NBHC program is at «»

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.